Screening for pre‐eclampsia at 11–13 weeks' gestation: use of pregnancy‐associated plasma protein‐A, placental growth factor or both

May 23, 2020Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology

Early pregnancy screening for pre-eclampsia using pregnancy protein A, placental growth factor, or both

AI simplified

Abstract

In a study of 60,875 singleton pregnancies, 2.9% developed pre-eclampsia (PE) by < 37 weeks' gestation.

  • Screening for PE using maternal factors, mean arterial pressure (MAP), uterine artery pulsatility index (UtA-PI), and placental growth factor (PlGF) led to a detection rate of 74.1% at a screen-positive rate of 10%.
  • The addition of serum pregnancy-associated plasma protein-A (PAPP-A) did not enhance the prediction of PE compared to the combination of maternal factors, MAP, UtA-PI, and PlGF.
  • Risk cut-offs and screen-positive rates for achieving a fixed detection rate of preterm PE varied based on racial composition and the biomarkers used.
  • For a desired detection rate of 75% in white women using PlGF, the risk cut-off was 1 in 136 with a screen-positive rate of 14.1%; in black women, the risk cut-off was 1 in 29 with a screen-positive rate of 12.5%.
  • Using PAPP-A instead of PlGF for the same detection rate in white women resulted in a risk cut-off of 1 in 140 with a screen-positive rate of 16.9%, while in black women, it was 1 in 44 with a screen-positive rate of 19.3%.

AI simplified

Full Text

what lands in your inbox each week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free